Fact checked byShenaz Bagha

Read more

November 08, 2022
1 min read
Save

Positive results announced in first part of phase 2 trial for TRD treatment

Fact checked byShenaz Bagha
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Biomind Labs Inc. has announced positive initial results from the first part of its phase 2 trial of a novel liquid inhaled formulation of N,N-Dimethyltryptamine, or DMT, for treatment-resistant depression.

According to a release from the company, the trial, led by Dráulio Araújo, PhD, has involved a dose exploration schedule of its formulation, BMND01, ranging from 5 mg to 100 mg. Thus far, no participant has presented serious adverse events or clinical risk to the 11 different doses tested.

Men looking at whiteboard
Biomind Labs Inc. announced positive initial results from a phase 2 trial of a novel liquid inhaled formulation of DMT for treatment-resistant depression. Source: Adobe Stock.

“This trial aims to go through the full psychedelic experience in just 10 minutes,” Biomind CEO Alejandro Antalich, said in the release. “These successful first results bring strong potential for the next phase of the trial, which will address patients suffering from TRD.”

The company stated in the release that the experimental design of the open-label ascending dose trial involved developing and implementing a proprietary clinical-experimental protocol based on the fundamentals of interventional psychiatry. This multidisciplinary approach combines a psychiatric procedure for dosing DMT associated with psychological support under strict clinical standards.

“By allowing the creation of specialized centers for the administration of DMT, it is possible to scale-up treatments without the need to train a whole new generation of mental health professionals,” Antalich said in the release.